The discovery of a potent and selective third-generation EGFR kinase inhibitor as a therapy for EGFR L858R/T790M double mutant non-small cell lung cancer-Reference-Cited by-同舟云学术

The discovery of a potent and selective third-generation EGFR kinase inhibitor as a therapy for EGFR L858R/T790M double mutant non-small cell lung cancer

Published:2019-12 Issue: Volume:183 Page:111709
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

An Baijiao,Pan Tingting,Hu Jinhui,Pang Yanqing,Huang Ling^ORCID,Chan Albert S.C.,Li Xingshu^ORCID,Yan Jun

Funder

Natural Science Foundation of Guangdong Province, China

the youth innovation project of Guangzhou university of Chinese Medicine, China

Science Foundation of Guangdong Provincial Hospital of Chinese Medicine, China

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference32 articles.

1. Signatures of drug sensitivity in nonsmall cell lung cancer;Gong;Int. J. Proteomics,2011

2. Challenges and perspectives on the development of small-molecule EGFR inhibitors against T790M-mediated resistance in non-small-cell lung cancer;Song;J. Med. Chem.,2016

3. Discovery of novel 2,4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation;Yan;Eur. J. Med. Chem.,2018

4. Role of AXL expression in non-small cell lung cancer;Qu;Oncol. Lett.,2016

5. Design, synthesis, SAR discussion, in vitro and in vivo evaluation of novel selective EGFR modulator to inhibit L858R/T790M double mutants;Zhang;Eur. J. Med. Chem.,2017

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the structural activity relationship of the Osimertinib: A covalent inhibitor of double mutant EGFRL858R/T790M tyrosine kinase for the treatment of Non-Small Cell Lung Cancer (NSCLC);Bioorganic & Medicinal Chemistry;2024-07

2. Late-stage modification of complex drug: Base-controlled Pd-catalyzed regioselective synthesis and bioactivity of arylated osimertinibs;Science Advances;2024-03-08

3. Rational design and synthesis of 2,4‐dichloro‐6‐methyl pyrimidine derivatives as potential selective EGFR^T790M/L858R inhibitors for the treatment of non‐small cell lung cancer;Archiv der Pharmazie;2024-02-21

4. Discovery of potent and effective inhibitors containing sulfoxide structures targeting EML4-ALK rearrangement and EGFR mutant non-small cell lung cancer;Bioorganic Chemistry;2023-09

5. An outlook of docking analysis and structure-activity relationship of pyrimidine-based analogues as EGFR inhibitors against non-small cell lung cancer (NSCLC);Journal of Biomolecular Structure and Dynamics;2023-08-29